BRPI0012265B8 - fator estimulante de colônia de granulócitos humano modificado e processo para produzir o mesmo - Google Patents

fator estimulante de colônia de granulócitos humano modificado e processo para produzir o mesmo

Info

Publication number
BRPI0012265B8
BRPI0012265B8 BRPI0012265A BRPI0012265A BRPI0012265B8 BR PI0012265 B8 BRPI0012265 B8 BR PI0012265B8 BR PI0012265 A BRPI0012265 A BR PI0012265A BR PI0012265 A BRPI0012265 A BR PI0012265A BR PI0012265 B8 BRPI0012265 B8 BR PI0012265B8
Authority
BR
Brazil
Prior art keywords
produce
csf
stimulating factor
colony stimulating
human granulocyte
Prior art date
Application number
BRPI0012265A
Other languages
English (en)
Portuguese (pt)
Inventor
Sun Lee Gwan
Chang Kwon Se
Min Bae Sung
Youb Jung Sung
Original Assignee
Hanmi Holdings Co Ltd
Hanmi Science Co Ltd
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36129291&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0012265(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Holdings Co Ltd, Hanmi Science Co Ltd, Hanmi Pharm Ind Co Ltd filed Critical Hanmi Holdings Co Ltd
Publication of BRPI0012265B1 publication Critical patent/BRPI0012265B1/pt
Publication of BRPI0012265B8 publication Critical patent/BRPI0012265B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0012265A 1999-07-08 2000-07-07 fator estimulante de colônia de granulócitos humano modificado e processo para produzir o mesmo BRPI0012265B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1019990027418A KR100356140B1 (ko) 1999-07-08 1999-07-08 인간 과립구 콜로니 자극인자 변이체 및 이의 생산 방법
PCT/KR2000/000733 WO2001004329A1 (en) 1999-07-08 2000-07-07 Modified human granulocyte-colony stimulating factor and process for producing same

Publications (2)

Publication Number Publication Date
BRPI0012265B1 BRPI0012265B1 (pt) 2018-11-21
BRPI0012265B8 true BRPI0012265B8 (pt) 2021-05-25

Family

ID=36129291

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0012265A BRPI0012265B8 (pt) 1999-07-08 2000-07-07 fator estimulante de colônia de granulócitos humano modificado e processo para produzir o mesmo
BR0012265-3A BR0012265A (pt) 1999-07-08 2000-07-07 Fator estimulante de colÈnia de granulócitos humano modificado e processo para produzir o mesmo

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR0012265-3A BR0012265A (pt) 1999-07-08 2000-07-07 Fator estimulante de colÈnia de granulócitos humano modificado e processo para produzir o mesmo

Country Status (16)

Country Link
US (2) US20040224393A1 (enExample)
EP (1) EP1194575B2 (enExample)
JP (1) JP2003504069A (enExample)
KR (1) KR100356140B1 (enExample)
CN (1) CN1195859C (enExample)
AT (1) ATE299187T1 (enExample)
AU (1) AU757147C (enExample)
BR (2) BRPI0012265B8 (enExample)
CA (1) CA2378543C (enExample)
DE (1) DE60021188T3 (enExample)
DK (1) DK1194575T4 (enExample)
ES (1) ES2243275T5 (enExample)
NZ (1) NZ516476A (enExample)
PT (1) PT1194575E (enExample)
RU (1) RU2232772C2 (enExample)
WO (1) WO2001004329A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
IL159524A0 (en) 2001-07-11 2004-06-01 Maxygen Holdings Ltd G-csf conjugates
US7611700B2 (en) * 2002-09-09 2009-11-03 Hanall Pharmaceuticals, Co., Ltd. Protease resistant modified interferon alpha polypeptides
US8338373B2 (en) * 2003-10-24 2012-12-25 Nora Therapeutics, Inc. Method for reducing the risk of spontaneous abortion in a human female subject
EP2198875A1 (en) 2003-10-24 2010-06-23 Nora, LLC A method for reducing the likelihood of preterm labour in a subject in need thereof
US20090226397A1 (en) 2003-10-24 2009-09-10 Nora Therapeutics, Inc. Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
AU2006254543A1 (en) 2005-06-01 2006-12-07 Maxygen Holdings Ltd. PEGylated G-CSF polypeptides and methods of producing same
DE102005033250A1 (de) 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
EP2274325A4 (en) * 2008-05-13 2011-05-25 Nora Therapeutics Inc ANALOGUE OF HUMAN G-CSF AND METHOD OF MANUFACTURE AND APPLICATION THEREOF
JP5657698B2 (ja) 2010-01-19 2015-01-21 ハンミ サイエンス カンパニー リミテッドＨａｎｍｉ Ｓｃｉｅｎｃｅｃｏ．，Ｌｔｄ． 持続型顆粒球コロニー刺激因子結合体の液剤
TWI600759B (zh) 2010-04-02 2017-10-01 可娜公司 藉由抑制群落刺激因子３（ｃｓｆ３）之天然反義轉錄物以治療ｃｓｆ３相關疾病
KR101831300B1 (ko) 2010-10-29 2018-02-23 한미사이언스 주식회사 재조합 대장균으로부터 인간 과립구 콜로니 자극인자를 정제하는 방법
RU2467764C2 (ru) * 2011-01-12 2012-11-27 Государственное бюджетное образовательное учреждение дополнительного профессионального образования "Пензенский институт усовершенствования врачей" Министерства здравоохранения и социального развития Российской Федерации Способ лечения больных аутоиммунной хронической крапивницей с использованием внутривенного введения препарата "габриглобин"
KR101623906B1 (ko) 2014-07-23 2016-05-24 주식회사 이큐스앤자루 과립구 콜로니 자극인자 변이 단백질 또는 이의 트랜스페린 융합 단백질을 유효성분으로 포함하는 약학적 조성물
WO2016013725A1 (ko) * 2014-07-23 2016-01-28 주식회사 이큐스앤자루 과립구 콜로니 자극인자 변이 단백질 또는 이의 트랜스페린 융합 단백질을 유효성분으로 포함하는 약학적 조성물
KR102645064B1 (ko) 2017-02-03 2024-03-08 한미약품 주식회사 지속성이 증가된 생리활성 물질의 결합체 및 이의 용도
US11267858B2 (en) 2019-05-31 2022-03-08 Spectrum Pharmaceuticals, Inc. Methods of treatment using G-CSF protein complex
US11684655B2 (en) 2019-05-31 2023-06-27 Spectrum Pharmaceuticals, Inc. Methods of treating neutorpenia using G-CSF protein complex
KR102375269B1 (ko) * 2021-01-27 2022-03-17 한미약품 주식회사 단백질 액상 제제 및 이의 제조방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPH01500483A (ja) * 1986-08-11 1989-02-23 シタス　コーポレイション Ｇ‐ｃｓｆ及びそのミューテインの発現
US5362853A (en) * 1986-12-23 1994-11-08 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US5714581A (en) * 1986-12-23 1998-02-03 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
JPH02104598A (ja) 1988-04-12 1990-04-17 Kirin Amgen Inc ヒト顆粒球コロニー刺激因子ポリペプチド誘導体
NZ236819A (en) 1990-02-03 1993-07-27 Max Planck Gesellschaft Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
EP0626448A3 (de) 1993-05-26 1998-01-14 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Herstellung und Reinigung von alpha-Interferon
US6476198B1 (en) 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules
US5451660A (en) * 1993-12-13 1995-09-19 Genentech, Inc. Method for purifying polypeptides
EP0789776B1 (en) 1994-11-01 2001-06-13 Winfried Wels Nucleic acid transfer system
US6100070A (en) 1995-10-05 2000-08-08 G. D. Searle & Co. G-CSF receptor agonists
KR100316347B1 (ko) * 1998-09-15 2002-08-27 한미약품(주) 대장균엔테로톡신ⅱ신호펩티드의변형체와인체성장호르몬의융합단백질을발현하는재조합미생물및그를이용한인체성장호르몬의제조방법
NZ522847A (en) * 2000-05-16 2004-11-26 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues

Also Published As

Publication number Publication date
RU2232772C2 (ru) 2004-07-20
WO2001004329A1 (en) 2001-01-18
JP2003504069A (ja) 2003-02-04
KR100356140B1 (ko) 2002-10-19
ATE299187T1 (de) 2005-07-15
EP1194575A4 (en) 2002-10-24
DE60021188D1 (de) 2005-08-11
CN1195859C (zh) 2005-04-06
ES2243275T3 (es) 2005-12-01
KR20010009171A (ko) 2001-02-05
AU5710600A (en) 2001-01-30
CA2378543A1 (en) 2001-01-18
EP1194575A1 (en) 2002-04-10
BR0012265A (pt) 2002-03-12
ES2243275T5 (es) 2009-12-02
DK1194575T3 (da) 2005-10-17
AU757147C (en) 2005-03-03
EP1194575B1 (en) 2005-07-06
BRPI0012265B1 (pt) 2018-11-21
US20040224393A1 (en) 2004-11-11
PT1194575E (pt) 2005-10-31
NZ516476A (en) 2003-09-26
US7704709B2 (en) 2010-04-27
EP1194575B2 (en) 2009-08-26
DE60021188T2 (de) 2006-04-27
US20080064066A1 (en) 2008-03-13
DK1194575T4 (da) 2009-12-07
DE60021188T3 (de) 2010-04-01
CN1360636A (zh) 2002-07-24
CA2378543C (en) 2010-05-18
AU757147B2 (en) 2003-02-06

Similar Documents

Publication Publication Date Title
BR0012265A (pt) Fator estimulante de colÈnia de granulócitos humano modificado e processo para produzir o mesmo
DE69739715D1 (de) Herstellungsverfahren von 1,3-propandiol durch rekombinante organismen
DE69929805D1 (de) Modifiziertes e.coli enterotoxin ii signalpeptid sowie ein mikroorganismus der ein fusionsprotein sowie ein heterologes protein exprimiert
ATE513045T1 (de) Stamm von escherichia coli überproduzierend l- threonine, und verfahren zur herstellung von l- threoninen durch fermentation
EP1095158A4 (en) METHOD AND MATERIALS FOR THE PRODUCTION OF GLUCOSAMINE
DE69521752D1 (de) Verfahren für die Herstellung von Proteinen
NZ600690A (en) Fkbp-l and uses thereof
BR9802403A (pt) Proteìna tendo atividade transglutaminase, dna, transformante, e, processo para produzir uma proteìna tendo uma atividade transglutaminase.
ATE280222T1 (de) Alkaline protease, verfahren zu ihrer herstellung,anwendung derselben und diese herstellende mikroorganismen
DE69736389D1 (de) Proteine mit zellulase-aktivitäten und prozess für ihre herstellung
ATE338129T1 (de) Herstellung gegen sclerotinia sclerotiorum resistenter pflanzendurch einführung eines für oxalatoxydase kodierenden gens
BRPI0107708A8 (pt) Vetor de expressão e secreção para interferon alfa humano e processo para produzir interferon alfa humano empregando o mesmo
DE60206622D1 (de) Verfahren zur herstellung von d-pantothensäure und/oder deren salzen
DE60328813D1 (de) Mutanten für die herstellung von d-aminosäuren
CA2506647A1 (en) Method for digesting proteins highly resistant to denaturation and degradation
DE69031996D1 (de) Menschlicher rekombinanter plazentaler ribonuklease-inhibitor und verfahren zur herstellung
ATE451469T1 (de) In vivo-verfahren zur herstellung von proteinen, die nicht-konventionelle aminosäuren enthalten
DE60033823D1 (de) Rekombinante mikroorganismen
MXPA02008010A (es) Enterotoxina estafilococica sec-ser, vector de expresion y celula huesped, metodo de produccion de los mismos y metodo de fabricacion de vacuna.
YU3999A (en) Novel strains of echerichia coli, methods of preparing the same and use thereof in fermentation processes for l-threonine production
CN86102686A (zh) 龋齿预防制剂和制备该制剂的方法